Clinical Trial Update: A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas [Phase 1]

View source ↗

Summary

A completed Phase 1 study evaluating XL765 in combination with temozolomide with or without radiation in adults with malignant gliomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme
• Malignant Glioma

Drugs mentioned

• Temozolomide (Temozolomide)
• XL765 (SAR245409) (SAR245409)

Snippet

Sponsor: Sanofi | Conditions: Mixed Gliomas, Malignant Gliomas | Phase 1 | Status: COMPLETED